Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali and Niger.
Somé AF, Zongo I, Sagara I, Ibrahim A, Ahanhanzo CD, Agbanouvi-Agassi EE, Sayi DA, Toe LP, Kabré Z, Nikiéma F, Bazié T, Ouédraogo S, Sombié I, Dicko A, Adehossi E, Ouédraogo JB, Dabiré KR. Somé AF, et al. Trop Med Infect Dis. 2022 Aug 29;7(9):214. doi: 10.3390/tropicalmed7090214. Trop Med Infect Dis. 2022. PMID: 36136625 Free PMC article.
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouédraogo JB, Rosenthal PJ. Somé AF, et al. Antimicrob Agents Chemother. 2010 May;54(5):1949-54. doi: 10.1128/AAC.01413-09. Epub 2010 Mar 15. Antimicrob Agents Chemother. 2010. PMID: 20231394 Free PMC article.
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, Rosenthal PJ, Sutherland C, Nosten F, Ouedraogo JB. Zongo I, et al. Among authors: some af. Antimicrob Agents Chemother. 2015 Aug;59(8):4387-96. doi: 10.1128/AAC.04923-14. Epub 2015 Apr 27. Antimicrob Agents Chemother. 2015. PMID: 25918149 Free PMC article. Clinical Trial.
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.
Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé AF, Coulibaly AS, Traore OB, Dara N, Kabore MJ, Thera I, Compaore YD, Sylla MM, Nikiema F, Diallo MS, Dicko A, Gil JP, Borrmann S, Duparc S, Miller RM, Doumbo OK, Shin J, Bjorkman A, Ouedraogo JB, Sirima SB, Djimdé AA. Sagara I, et al. Among authors: some af. Lancet Infect Dis. 2016 Feb;16(2):189-98. doi: 10.1016/S1473-3099(15)00318-7. Epub 2015 Oct 23. Lancet Infect Dis. 2016. PMID: 26601738 Free PMC article. Clinical Trial.
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Lancet. 2018 Apr 7;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. Epub 2018 Mar 29. Lancet. 2018. PMID: 29606364 Free PMC article. Clinical Trial.
Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso.
Compaoré YD, Zongo I, Somé AF, Barry N, Nikiéma F, Kaboré TN, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga RS, Sagara I, Djimdé A, Ouédraogo JB. Compaoré YD, et al. Among authors: some af. Malar J. 2021 Jan 29;20(1):64. doi: 10.1186/s12936-021-03593-6. Malar J. 2021. PMID: 33514368 Free PMC article.
20 results